Qurient Co. Ltd (115180 KQ) stock market data APIs
₩12039.3018
121.6(1%)
as of June 23, 2025
Try our APIs with
free plan!
Qurient Co. Ltd Financial Data Overview
Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company's pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM. Its pipeline products also comprise Adrixetinib (Q702), an Axl/Mer/CSF1R Inhibitor, which completed phase I for the treatment of solid tumors; and Q901, a selective CDK7 inhibitor, is under Phase I stage for treating solid tumors. The company was formerly known as Quro Science Inc. and changed its name to Qurient Co., Ltd. in October 2011. Qurient Co., Ltd. was founded in 2008 and is headquartered in Seongnam-si, South Korea.
Prev. Close
12039.3018
Open
12160.9028
High
12306.9044
Low
11596.2983
52 wk Range
3200-12930
Market Cap
396 290 M
Shares Outstanding
33 641 K
Revenue
8 988 M
EPS
-184.1536
Beta
0.719
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Qurient Co. Ltd data using free add-ons & libraries
Get Qurient Co. Ltd Fundamental Data
Qurient Co. Ltd Fundamental data includes:
- Net Revenue: 8 988 M
- EBITDA: -27 596 042 240
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Qurient Co. Ltd News
New
Qurient Announces Dosing of First Patient in Q702 in Combination with KEYTRUDA® in a Phase 1b/2 Clinical Study for the Treatment of Patients with Solid Tumors
SEOUL, South Korea, January 31, 2023--(BUSINESS WIRE)--Qurient Co. Ltd. (KRX: 115180), a clinical-stage biotech company based in Korea, today announced that the first patient has been dosed in the Pha...
Qurient Announces Dosing of First Patient in Q901 Phase 1/2 Clinical Study for the Treatment of Patients with Solid Tumors
SEOUL, South Korea, December 01, 2022--(BUSINESS WIRE)--Qurient Co. Ltd. (KRX: 115180), a clinical-stage biotech company based in Korea, today announced that the first patient has been dosed in the Ph...
Qurient Announces Collaboration Agreement with MSD to Evaluate Selective CDK7 Inhibitor Q901 in Combination With KEYTRUDA® (pembrolizumab)
Q901 is a novel highly selective CDK7 inhibitor Q901 is ready for dose escalation study in the U.S. for the treatment of selected advanced solid tumors (NCT05394103) The phase 1/2 study of Q901 and KE...
Qurient Announces U.S. FDA Clearance of IND Application for Q901, a Novel Cancer Therapy
Phase 1/2 clinical study in patients with advanced solid tumor expected to start in 2Q2022 SEONGNAM-SI, South Korea, February 08, 2022--(BUSINESS WIRE)--Qurient Co. Ltd. (KRX: 115180), a clinical sta...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
